country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-184710

Copy Link Print Information

COX-2-IN-69

COX-2-IN-69 is a selective, orally active COX-2 inhibitor with an IC₅₀ of 0.90 μM. COX-2-IN-69 occupies the secondary pocket of COX-2, interacts with His90 and Arg513, and reduces serum levels of PGE₂, IL-1β and TNF-α. COX-2-IN-69 exerts anti-inflammatory activity in a rat paw swelling model. COX-2-IN-69 can be used in inflammation-related research.

For research use only. We do not sell to patients.

Formula: C₂₁H₁₉BrN₂O
Molecular Weight:395.29

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

COX-2-IN-69 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vivo

COX-2-IN-69 (Compound 4c) (10 mg/kg; p.o.; single administration) exhibits potent in vivo anti-inflammatory activity in a rat paw edema model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague Dawley (male, 130-150 g, Carrageenan (HY-125474)-induced paw edema model)^[1]
Dosage:

10 mg/kg
Administration:

p.o.; single dose
Result:

Reduced paw edema percentage to 9.91% at 3 hours post-Carrageenan injection.
Showed no significant difference in paw volume compared to normal control at 2 and 3 hours.
Reduced serum PGE2 levels by 59.37%, serum IL-1β levels by 57.81%, and serum TNF-α levels by 54.70% compared to the Carrageenan control group.
Caused moderate desquamation of gastric mucosa, inflammatory cell infiltration of the submucosa layer, and vacuolar degeneration of gastric glands.

Chemical Information

Molecular Weight 395.29
Formula C₂₁H₁₉BrN₂O
SMILES

BrC(C=C1)=CC=C1CC2=CC(/C=C/C3=C(C)C=C(C)C=C3)=NNC2=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Elbahrawy AH, et al. Design, synthesis, biological evaluation and histopathological studies of Pyridazine and Pyrazoline derivatives as potential anti-inflammatory agents. Bioorganic chemistry. 2026 Jun 24;180:110164. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote